Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | FAP | Q12884 | 4/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15374838 | 0.98 | MEN1 (0.47) | KMT2AMEN1KDM4ENPSR1DPP7 | |
| SCHEMBL15374839 | 0.94 | MEN1 (0.44) | KMT2AMEN1KDM4ENPSR1DPP7 | |
| SCHEMBL7004377 | 0.89 | — | — | |
| SCHEMBL13793412 | 0.82 | EPHX2 (0.43) | KMT2AMEN1KDM4EDPP7LMNA | |
| SCHEMBL19415011 | 0.81 | KDM4E (0.42) | KMT2AMEN1KDM4ENPSR1DPP7 | |
| SCHEMBL5103623 | 0.81 | LMNA (0.63) | KMT2AKDM4ENPSR1LMNAALDH1A1 | |
| SCHEMBL13793612 | 0.80 | KDM4E (0.36) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL16257428 | 0.80 | EPHX1 (0.45) | KMT2AMEN1KDM4EDPP7DPP4 | |
| SCHEMBL6623662 | 0.79 | MEN1 (0.47) | KMT2AMEN1KDM4ENPSR1LMNA | |
| SCHEMBL16103851 | 0.79 | DPP7 (0.47) | KMT2AMEN1KDM4EDPP7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142543-B2 | Antidepressant compound and preparation method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-10-12 | — | — | US | disclosed |
| US-20200385418-A1 | ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-12-10 | — | — | US | disclosed |
| EP-3564253-A1 | ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-11-06 | — | — | EP | disclosed |
| EP-2470500-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-0848957-A1 | Fas LIGAND SOLUBILIZATION INHIBITOR | KANEBO LTD. (JP) | 1998-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142543-B2 | Antidepressant compound and preparation method and application thereof | TPH1, BDNF, CRH | KMT2A 2317/4885MEN1 2812/4885KDM4E 1171/4885 |
| US-20200385418-A1 | ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | TPH1, BDNF, CRH | KMT2A 2317/4885MEN1 2812/4885KDM4E 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.